- Home
- AGL vs GPCR Comparison
AGL vs GPCR Comparison
Compare AGL & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGL
- GPCR
- Stock Information
- Founded
- AGL 2016
- GPCR 2016
- Country
- AGL United States
- GPCR United States
- Employees
- AGL 1076
- GPCR N/A
- Industry
- AGL Managed Health Care
- GPCR
- Sector
- AGL Health Care
- GPCR
- Exchange
- AGL Nasdaq
- GPCR Nasdaq
- Market Cap
- AGL 923.1M
- GPCR 1.1B
- IPO Year
- AGL 2021
- GPCR 2023
- Fundamental
- Price
- AGL $2.15
- GPCR $21.52
- Analyst Decision
- AGL Hold
- GPCR Strong Buy
- Analyst Count
- AGL 20
- GPCR 8
- Target Price
- AGL $4.47
- GPCR $79.29
- AVG Volume (30 Days)
- AGL 5.0M
- GPCR 742.3K
- Earning Date
- AGL 05-06-2025
- GPCR 05-08-2025
- Dividend Yield
- AGL N/A
- GPCR N/A
- EPS Growth
- AGL N/A
- GPCR N/A
- EPS
- AGL N/A
- GPCR N/A
- Revenue
- AGL $5,988,958,000.00
- GPCR N/A
- Revenue This Year
- AGL N/A
- GPCR N/A
- Revenue Next Year
- AGL $10.11
- GPCR N/A
- P/E Ratio
- AGL N/A
- GPCR N/A
- Revenue Growth
- AGL 23.07
- GPCR N/A
- 52 Week Low
- AGL $1.50
- GPCR $13.22
- 52 Week High
- AGL $7.73
- GPCR $57.60
- Technical
- Relative Strength Index (RSI)
- AGL 32.82
- GPCR 41.59
- Support Level
- AGL $2.09
- GPCR $21.38
- Resistance Level
- AGL $2.37
- GPCR $22.98
- Average True Range (ATR)
- AGL 0.15
- GPCR 1.17
- MACD
- AGL 0.04
- GPCR -0.39
- Stochastic Oscillator
- AGL 14.58
- GPCR 11.01
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.